# US 2014/0275119 A1 · Compounds and compositions for the treatment of parasitic diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0275119 A1
- Document ID: US20140275119A1
- Status: Published application
- Kind: A1
- Application number: 14/209,850
- Filed: 2014-03-13
- Published: 2014-09-18
- Earliest claimed: 2013-03-15
- Assignees: Novartis AG; Irm LLC
- Inventors: Fang LIANG; Pranab Kumar MISHRA; Valentina MOLTENI; Advait Suresh NAGLE; Frantisek SUPEK; Liying Jocelyn TAN; Agnes VIDAL
- Web page: https://patentgrep.com/patent/US20140275119A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt, or stereoisomer thereof; wherein
L1 is —C(O)— or —S(O)2—;
R1 is selected from nitro, C1-4alkyl, C1-6alkoxy, amino, C5-9heteroaryl, C3-6cycloalkyl and C4-6heterocycloalkyl, each of which is optionally substituted by 1-2 substituent independently selected from halo, cyano, amino, C1-4alkyl, haloC1-4alkyl, C1-6alkoxy, and C1-4alkylcarbonyl; or —NHL1R1 is nitro;
R3 is selected from hydrogen, halo, cyano, C1-4alkyl and haloC1-4alkyl;
R4 is selected from hydrogen, C1-4alkyl, haloC1-4alkyl, and —C(O)R10, wherein R10 is hydroxy, C1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino, C3-6cycloalkyl and C4-6heterocycloalkyl, each of which is independently optionally substituted by 1-2 substituents independently selected from hydroxyl, halo and C1-4alkyl;
L3 is a bond, phenylene, or C5-6heteroarylene;
R0 is selected from hydrogen, hydroxyl, halo, nitro, —N═CHN(CH3)2, C1-4alkyl, C1-4alkoxy, —NR2aR2b, —NR5C(O)R6, —NR5S(O)2R8, C3-6cycloalkyl, C4-6heterocycloalkyl, C4-6heterocycloalkenyl, phenyl and C5-6heteroaryl; wherein
the C1-4alkyl or C1-4alkoxy is optionally substituted by 1-2 substituents independently selected from C1-4alkoxy, amino, phenyl and C5-6heteroaryl; wherein the phenyl or C5-6heteroaryl is optionally further substituted by halo or C1-4alkyl;
the C3-6cycloalkyl, C4-6heterocycloalkyl, C4-6heterocycloalkenyl, phenyl and C5-6heteroaryl of R0 is optionally substituted with halo, oxo, C1-4alkyl, hydroxyC1-4alkyl, haloC1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino, and —(CH2)1-4NRaRb, wherein Ra and Rb are each independently hydrogen, C1-4alkyl or C3-6cycloalkyl;
R2a is hydrogen or C1-4alkyl;
R2b is selected from hydrogen, C1-4alkyl, wherein the alkyl is optionally substituted by amino, C4-6heterocycloalkyl, phenyl or C5-6heteroaryl, wherein the C4-6heterocycloalkyl, phenyl or C5-6heteroaryl is further optionally substituted by hydroxyl, halo or C1-4alkyl;
R5 is hydrogen or C1-4alkyl;
R6 is selected from hydrogen, C1-6alkyl, C1-4alkoxy, C3-6cycloalkoxy, amino, C3-6cycloalkyl, C5-6heterocycloalkyl, and C5-6heteroaryl, wherein
the C1-4alkyl, C1-4alkoxy, C3-6cycloalkoxy, and amino of R6 are each optionally substituted by 1-2 substituents independently selected from halo, hydroxy, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, —NR9aR9b, C3-6cycloalkyl, C5-6heterocycloalkyl, and C5-6heteroaryl, wherein R9a is hydrogen or C1-4alkyl and R9b is selected from hydrogen, C1-4alkyl, C1-4alkylcarbonyl and C1-4alkoxycarbonyl, and the C5-6heterocycloalkyl and C5-6heteroaryl are each further optionally substituted by 1-2 substituents independently selected from hydroxyl, C1-4alkyl and C1-4alkoxycarbonyl,
the C5-6heteroaryl of R6 is optionally substituted with 1-2 substituents selected from hydroxy, C1-4alkyl, and C1-4alkoxycarbonyl,
the C3-6cycloalkyl or C4-6heterocycloalkyl of R6 are each independently optionally substituted by 1-2 substituents independently selected from halo, cyano, hydroxy, C1-4alkyl, haloC1-4alkyl, C1-4alkoxylC1-4alkyl, aminocarbonyl, C1-4alkoxycarbonyl, and C1-4alkoxycarbonylaminoC1-4alkyl, and
R8 is C1-4alkyl or C1-4alkylamino.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein L1 is —C(O)—.

### Claim 3 (depends on 2)

The compound according to claim 2, wherein R1 is selected from C1-4alkyl, C1-6alkoxy, amino, C5-9heteroaryl, C3-6cycloalkyl and C4-6heterocycloalkyl, each is optionally substituted by 1-2 substituent independently selected from hydroxyl, halo, cyano, amino, C1-4alkyl, haloC1-4alkyl, C1-6alkoxy, C1-4alkylcarbonyl, phenyl and C5-6heteroaryl.

### Claim 4 (depends on 2)

The compound according to claim 2, wherein R1 is selected from C5-9heteroaryl, C4-6heterocycloalkyl, and C3-6cycloalkyl, each of which is independently optionally substituted by 1-2 substituents independently selected from halo, cyano, C1-4alkyl and C1-4alkoxy.

### Claim 5 (depends on 2)

The compound according to claim 2, wherein R1 is selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thiophenyl, thiazolyl, phenyl, pyrazinyl, cyclopropyl, cyclopentyl, pyrrolidinyl, and indolyl, each of which is independently optionally substituted by 1-2 substituents independently selected from halo, cyano, C1-4alkyl, haloC1-4alkyl and C1-4alkylcarbonyl.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein L1-R1 is selected from

### Claim 7 (depends on 1)

The compound according to claim 1, wherein L1-R1 is selected from

### Claim 8 (depends on 3)

The compound according to claim 3, wherein R3 is selected from hydrogen, halo, methyl, or trifluoromethyl.

### Claim 9 (depends on 3)

The compound according to claim 3, wherein R3 is chloro or fluoro,

### Claim 10 (depends on 9)

The compound according to claim 9, wherein R4 is hydrogen.

### Claim 11 (depends on 10)

The compound according to claim 10, wherein R0 is selected from hydrogen, halo, nitro, C1-4alkyl, —N═CHN(CH3)2, —NHR2b, —NR5C(O)R6, —NR5S(O)2R8, C4-6heterocycloalkyl, C4-6heterocycloalkenyl, phenyl and C5-6heteroaryl; wherein
the C4-6heterocycloalkyl, C4-6heterocycloalkenyl, phenyl and C5-6heteroaryl of R0 is optionally substituted with oxo, C1-4alkyl, —(CH2)1-4OH, and —(CH2)1-4NRaRb, wherein Ra and Rb are each independently hydrogen, C1-4alkyl or C3-6cycloalkyl;
R2b is selected from hydrogen, C1-4alkyl, wherein the alkyl is optionally substituted by amino, C4-6heterocycloalkyl, phenyl or C5-6heteroaryl, wherein the C4-6heterocycloalkyl, phenyl or C5-6heteroaryl is further optionally substituted by hydroxy or halo;
R5 is hydrogen or C1-4alkyl;
R6 is selected from hydrogen, C1-6alkyl, C1-4alkoxy, C3-6cycloalkoxy, amino, C3-6cycloalkyl, C5-6heterocycloalkyl, and C5-6heteroaryl, wherein
the C1-4alkyl, C1-4alkoxy, C3-6cycloalkoxy, and amino of R6 are each optionally substituted by 1-2 substituents independently selected from halo, hydroxy, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, —NR9aR9b, C5-6heterocycloalkyl, and C5-6heteroaryl, wherein R9a is hydrogen or C1-4alkyl, and R9b is selected from hydrogen, C1-4alkyl, and C1-4alkoxycarbonyl; and the C5-6heterocycloalkyl and C5-6heteroaryl are each further optionally substituted by 1-2 substituents independently selected from hydroxyl, C1-4alkyl and C1-4alkoxycarbonyl;
the C5-6heteroaryl of R6 is optionally substituted with 1 to 2 C1-4alkyl;
the C3-6cycloalkyl or C4-6heterocycloalkyl of R6 are each independently optionally substituted by 1-2 substituents independently selected from halo, cyano, hydroxy, C1-4alkyl, haloC1-4alkyl, —CH2OCH3, —C(O)NH2, C1-4alkoxycarbonyl and C1-4alkoxycarbonylaminoC1-4alkyl; and
R8 is C1-4alkyl or C1-4alkylamino.

### Claim 12 (depends on 10)

The compound according to claim 10, wherein R0 is selected from hydrogen, halo, nitro, hydroxyl, C1-4alkoxy, amino, C1-4alkylamino, —NH(CH2)1-2-phenyl, —NR5C(O)R6, —NR5S(O)2R8, oxazolidin-2-one, 1,2,4-triazol-5(4H)-one, pyrrolidin-2-one, phenyl and C5-6heteroaryl; wherein
the oxazolidin-2-one, 1,2,4-triazol-5(4H)-one, pyrrolidin-2-one, phenyl or C5-6heteroaryl is optionally substituted with halo, C1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino, —(CH2)1-4OH, and —(CH2)1-4NRaRb, wherein Ra and Rb are each independently hydrogen, C1-4alkyl or C3-6cycloalkyl;
R5 is hydrogen or C1-4alkyl;
R6 is selected from C1-6alkyl, C1-6alkoxyl, C3-6cycloalkyl, C5-6heterocycloalkyl, and C5-6heteroaryl, each of which is optionally substituted with 1 to 2 substituents independently selected from hydroxyl, C1-4alkoxy, amino, C1-4alkylamino; and
R8 is C1-4alkyl or C1-4alkylamino.

### Claim 13 (depends on 10)

The compound according to claim 10, wherein -L3R0 is —NHC(O)OCH(CH3)2, —NHC(O)OCH2CH3, —NHC(O)OCH3, nitro,

### Claim 14 (depends on 1)

The compound according to claim 1 selected from:
propan-2-yl N-{2-[2-chloro-5-(5-fluorofuran-2-amido)phenyl]imidazo[1,2-a]pyrimidin-6-yl}carbamate;
propan-2-yl N-(2-{2-chloro-5-[(pyrrolidin-1-yl)carbonylamino]phenyl}imidazo[1,2-a]pyrimidin-6-yl)carbamate;
propan-2-yl N-{2-[3-(5-fluorofuran-2-amido)phenyl]imidazo[1,2-a]pyrimidin-6-yl}carbamate;
propan-2-yl N-(2-{2-chloro-5-[(3,3-difluoropyrrolidin-1-yl)carbonylamino]phenyl}imidazo[1,2-a]pyrimidin-6-yl)carbamate;
propan-2-yl N-(2-{3-[(pyrrolidin-1-yl)carbonylamino]phenyl}imidazo[1,2-a]pyrimidin-6-yl)carbamate;
propan-2-yl N-[2-(3-{[ethyl(methyl)carbamoyl]amino}phenyl)imidazo[1,2-a]pyrimidin-6-yl]carbamate;
propan-2-yl N-{2-[3-(pyrazine-2-amido)phenyl]imidazo[1,2-a]pyrimidin-6-yl}carbamate;
propan-2-yl N-{2-[3-(furan-2-amido)phenyl]imidazo[1,2-a]pyrimidin-6-yl}carbamate;
propan-2-yl N-[2-(5-{[ethyl(methyl)carbamoyl]amino}-2-fluorophenyl)imidazo[1,2-a]pyrimidin-6-yl]carbamate;

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A pharmaceutical composition comprising a compound according to any one of claims 1 to 14 as an active ingredient and at least one excipient.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, comprising administering to a subject a therapeutically effective amount of a compound according to any one of claims 1-14, wherein the disease is selected from Leishmaniasis, Human African Trypanosomiasis and Chagas disease, and wherein the administering is optionally in combination with a second agent.

### Claim 17 (depends on 15)

A method for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, comprising administering to a subject a therapeutically effective amount of a composition according to claim 15, wherein the disease is selected from Leishmaniasis, Human African Trypanosomiasis and Chagas disease, and wherein the administering is optionally in combination with a second agent.
propan-2-yl N-(2-{3-[(ethoxycarbonyl)amino]phenyl}imidazo[1,2-a]pyrimidin-6-yl)carbamate;
propan-2-yl N-{2-[3-(1,3-thiazole-2-amido)phenyl]imidazo[1,2-a]pyrimidin-6-yl}carbamate;
propan-2-yl N-{2-[2-fluoro-5-(furan-2-amido)phenyl]imidazo[1,2-a]pyrimidin-6-yl}carbamate;
propan-2-yl N-{2-[3-(5-methylfuran-2-amido)phenyl]imidazo[1,2-a]pyrimidin-6-yl}carbamate;
propan-2-yl N-[2-(3-{[methoxy(methyl)carbamoyl]amino}phenyl)imidazo[1,2-a]pyrimidin-6-yl]carbamate;
propan-2-yl N-(2-{2-chloro-5-[(pyrrolidin-1-yl)carbonylamino]phenyl}-3-fluoroimidazo[1,2-a]pyrimidin-6-yl)carbamate;
propan-2-yl N-(2-{3-[(diethylcarbamoyl)amino]phenyl}imidazo[1,2-a]pyrimidin-6-yl)carbamate;
propan-2-yl N-(2-{2-fluoro-5-[(pyrrolidin-1-yl)carbonylamino]phenyl}imidazo[1,2-a]pyrimidin-6-yl)carbamate;
propan-2-yl N-{2-[3-(5-chlorofuran-2-amido)phenyl]imidazo[1,2-a]pyrimidin-6-yl}carbamate;
propan-2-yl N-[2-(2-fluoro-5-nitrophenyl)imidazo[1,2-a]pyrimidin-6-yl]carbamate;
propan-2-yl N-(2-{3-[(dimethylcarbamoyl)amino]phenyl}imidazo[1,2-a]pyrimidin-6-yl)carbamate;
propan-2-yl N-[2-(3-{[(propan-2-yloxy)carbonyl]amino}phenyl)imidazo[1,2-a]pyrimidin-6-yl]carbamate;
propan-2-yl N-{2-[3-(2,4-dimethyl-1,3-oxazole-5-amido)phenyl]imidazo[1,2-a]pyrimidin-6-yl}carbamate;
propan-2-yl N-[2-(3-{[(2-methoxyethoxy)carbonyl]amino}phenyl)imidazo[1,2-a]pyrimidin-6-yl]carbamate;
methyl N-[4-(2-{2-chloro-5-[(pyrrolidin-1-yl)carbonylamino]phenyl}imidazo[1,2-a]pyrimidin-6-yl)phenyl]carbamate;
N-{4-chloro-3-[6-(4-fluorophenyl)imidazo[1,2-a]pyrimidin-2-yl]phenyl}pyrrolidine-1-carboxamide;
N-(4-chloro-3-{6-[4-(methylamino)phenyl]imidazo[1,2-a]pyrimidin-2-yl}phenyl)pyrrolidine-1-carboxamide;
methyl N-(4-{2-[2-chloro-5-(5-methylfuran-2-amido)phenyl]imidazo[1,2-a]pyrimidin-6-yl}phenyl)carbamate;
N-{4-chloro-3-[6-(thiophen-3-yl)imidazo[1,2-a]pyrimidin-2-yl]phenyl}pyrrolidine-1-carboxamide;
N-(4-chloro-3-{6-phenylimidazo[1,2-a]pyrimidin-2-yl}phenyl)pyrrolidine-1-carboxamide;
N-{4-chloro-3-[6-(thiophen-3-yl)imidazo[1,2-a]pyrimidin-2-yl]phenyl}-5-methylfuran-2-carboxamide;
N-(4-chloro-3-{6-phenylimidazo[1,2-a]pyrimidin-2-yl}phenyl)-5-methylfuran-2-carboxamide;
2-methoxyethyl N-[4-chloro-3-(6-{4-[(methoxycarbonyl)amino]phenyl}imidazo[1,2-a]pyrimidin-2-yl)phenyl]carbamate;
N-(4-chloro-3-{6-[4-(methylamino)phenyl]imidazo[1,2-a]pyrimidin-2-yl}phenyl)-5-methylfuran-2-carboxamide;
2-methoxyethyl N-{4-chloro-3-[6-(thiophen-3-yl)imidazo[1,2-a]pyrimidin-2-yl]phenyl}carbamate;
2-methoxyethyl N-(4-chloro-3-{6-phenylimidazo[1,2-a]pyrimidin-2-yl}phenyl)carbamate;
2-methoxyethyl N-(4-chloro-3-{6-[4-(methylamino)phenyl]imidazo[1,2-a]pyrimidin-2-yl}phenyl)carbamate;
ethyl N-(4-chloro-3-{6-[4-(methylamino)phenyl]imidazo[1,2-a]pyrimidin-2-yl}phenyl)carbamate;
N-(4-chloro-3-{6-chloroimidazo[1,2-a]pyrimidin-2-yl}phenyl)furan-2-carboxamide;
N-(4-chloro-3-{3-fluoro-6-phenylimidazo[1,2-a]pyrimidin-2-yl}phenyl)pyrrolidine-1-carboxamide;
propan-2-yl N-[2-(2-fluoro-5-{[(propan-2-yloxy)carbonyl]amino}phenyl)imidazo[1,2-a]pyrimidin-6-yl]carbamate;
propan-2-yl N-{2-[3-(5-methyl-1,3-thiazole-2-amido)phenyl]imidazo[1,2-a]pyrimidin-6-yl}carbamate; and
propan-2-yl N-[2-(3-cyclopropaneamidophenyl)imidazo[1,2-a]pyrimidin-6-yl]carbamate.
